Organicell Announces Positive Results of Their Expanded Access Trial for the Treatment of Mild to Moderate COVID-19 Using ZofinTM
MIAMI--(BUSINESS WIRE)--Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced the outcome of their expanded access (EA) intermediate size patient population trial (NCT04657406) which:
- Met endpoints for safety and efficacy in patients with mild to moderate COVID-19
- Mitigated mild and moderate symptoms
- Improved pulmonary opacities detected in chest X-rays
- Improved inflammatory biomarkers